Bellevue Group AG Has $12.53 Million Holdings in Evolent Health, Inc. (NYSE:EVH)

Bellevue Group AG decreased its stake in shares of Evolent Health, Inc. (NYSE:EVH - Free Report) by 58.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,113,658 shares of the technology company's stock after selling 1,556,392 shares during the period. Bellevue Group AG owned 0.96% of Evolent Health worth $12,529,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Barclays PLC lifted its position in shares of Evolent Health by 181.3% during the third quarter. Barclays PLC now owns 273,776 shares of the technology company's stock worth $7,742,000 after purchasing an additional 176,445 shares in the last quarter. Franklin Resources Inc. lifted its holdings in Evolent Health by 40.8% during the 3rd quarter. Franklin Resources Inc. now owns 909,776 shares of the technology company's stock worth $24,682,000 after buying an additional 263,815 shares in the last quarter. Principal Financial Group Inc. boosted its position in Evolent Health by 268.0% in the 3rd quarter. Principal Financial Group Inc. now owns 57,382 shares of the technology company's stock valued at $1,623,000 after buying an additional 41,788 shares during the last quarter. Nordea Investment Management AB increased its stake in shares of Evolent Health by 7.0% in the 4th quarter. Nordea Investment Management AB now owns 130,453 shares of the technology company's stock valued at $1,469,000 after buying an additional 8,552 shares during the period. Finally, Harbor Capital Advisors Inc. increased its stake in shares of Evolent Health by 90.1% in the 4th quarter. Harbor Capital Advisors Inc. now owns 803,211 shares of the technology company's stock valued at $9,036,000 after buying an additional 380,790 shares during the period.

Insider Activity

In related news, CEO Seth Blackley bought 55,225 shares of the business's stock in a transaction dated Thursday, March 6th. The stock was bought at an average price of $9.01 per share, for a total transaction of $497,577.25. Following the purchase, the chief executive officer now owns 762,217 shares in the company, valued at $6,867,575.17. This represents a 7.81 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Brendan B. Springstubb acquired 5,000 shares of the firm's stock in a transaction on Tuesday, March 4th. The stock was purchased at an average cost of $8.75 per share, for a total transaction of $43,750.00. Following the completion of the acquisition, the director now owns 11,842 shares in the company, valued at approximately $103,617.50. This represents a 73.08 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 74,000 shares of company stock valued at $666,315. 1.60% of the stock is owned by insiders.

Wall Street Analyst Weigh In

EVH has been the subject of several recent research reports. UBS Group dropped their price objective on Evolent Health from $27.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, January 16th. Canaccord Genuity Group dropped their price target on shares of Evolent Health from $23.00 to $16.00 and set a "buy" rating for the company in a research note on Thursday, January 23rd. Stephens reduced their price objective on shares of Evolent Health from $16.00 to $12.00 and set an "equal weight" rating on the stock in a research note on Tuesday, January 21st. Oppenheimer cut their price target on Evolent Health from $28.00 to $18.00 and set an "outperform" rating on the stock in a research note on Friday, January 24th. Finally, Citigroup decreased their price objective on Evolent Health from $21.00 to $18.00 and set a "buy" rating for the company in a research note on Friday, January 10th. One analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Evolent Health currently has a consensus rating of "Buy" and an average price target of $17.71.

Evolent Health Stock Down 13.2 %

EVH traded down $1.42 during trading hours on Friday, hitting $9.36. 3,136,870 shares of the company's stock were exchanged, compared to its average volume of 2,446,204. The stock has a market cap of $1.09 billion, a price-to-earnings ratio of -11.41 and a beta of 1.04. Evolent Health, Inc. has a 1-year low of $8.35 and a 1-year high of $33.63. The stock's 50-day moving average is $9.60 and its two-hundred day moving average is $11.72. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58.

Evolent Health (NYSE:EVH - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The technology company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.02). Evolent Health had a negative net margin of 2.41% and a positive return on equity of 5.73%. The company had revenue of $483.65 million during the quarter, compared to the consensus estimate of $460.15 million. During the same quarter in the previous year, the business earned $0.34 EPS. Evolent Health's revenue was down 24.4% on a year-over-year basis. Sell-side analysts predict that Evolent Health, Inc. will post 0.08 earnings per share for the current fiscal year.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.